Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Open Badges Research

Correlation of microrna-372 upregulation with poor prognosis in human glioma

Gang Li1, Zhiguo Zhang1, Yanyang Tu2, Tianbo Jin3, Hongjuan Liang1, Guangbin Cui4, Shiming He1* and Guodong Gao1*

Author Affiliations

1 Department of Neurosurgery, Tangdu hospital, the Fourth Military Medical University, No. 569, Xinsi Road, Xi’an, 710038, China

2 Department of Clinical Experimental Surgery, Tangdu hospital, the Fourth Military Medical University, Xi’an, 710038, China

3 National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an, 710069, China

4 Department of Radiology, Tangdu hospital, the Fourth Military Medical University, Xi’an, 710038, China

For all author emails, please log on.

Diagnostic Pathology 2013, 8:1  doi:10.1186/1746-1596-8-1

Published: 8 January 2013


MicroRNA-372 (miR-372) acts as either an oncogenic miRNA or an anti-oncomiR in various human malignancies. However, its roles in gliomas have not been elucidated. To address this problem, we here detected miR-372 expression in human gliomas and non-neoplastic brain tissues by real-time quantitative RT-PCR assay. The association of miR-372 expression with clinicopathological factors or prognosis of glioma patients was also statistically analyzed. As the results, miR-372 expression levels were significantly upregulated in glioma tissues compared to the corresponding non-neoplastic brain tissues (P<0.001). In addition, the high miR-372 expression was significantly associated with the advanced pathological grade (P=0.008) and the low Karnofsky performance score (KPS) of glioma patients (P=0.01). Moreover, the overall survival of patients with high miR-372 expression was dramatically shorter than those with low miR-372 expression (P<0.001). Furthermore, multivariate Cox regression analysis indicated that miR-372 expression was an independent prognostic factor for glioma patients (P=0.008). More importantly, subgroup analyses according to tumor pathological grade revealed that the cumulative overall survival of glioma patients with advanced pathological grades was significantly worse for high miR-372 expression group than for low miR-372 expression group (P<0.001), but no significant difference was found for patients with low pathological grades (P=0.08). Taken together, these data offer the convincing evidence for the first time that miR-372 may act as an oncogenic miRNA in gliomas and represent a potential regulator of aggressive development and a candidate prognostic marker for this malignancy, especially for advanced tumors with high pathological grades.

Virtual slides

The virtual slide(s) for this article can be found here: webcite

miR-372; Glioma; Real-time quantitative RT-PCR assay; Prognosis